R
Ralph B. D'Agostino
Researcher at Wake Forest University
Publications - 1336
Citations - 250792
Ralph B. D'Agostino is an academic researcher from Wake Forest University. The author has contributed to research in topics: Framingham Heart Study & Framingham Risk Score. The author has an hindex of 226, co-authored 1287 publications receiving 229636 citations. Previous affiliations of Ralph B. D'Agostino include VA Boston Healthcare System & University of Illinois at Urbana–Champaign.
Papers
More filters
Book
Goodness-of-Fit-Techniques
TL;DR: "Overview, Ralph B. D'Agostino and Michael A. Stephens Graphical Analysis and Tests of Chi-Squared Type, David S. Moore Tests Based on EDF Statistics, and tests for the Normal Distribution,"
Journal ArticleDOI
On the C-statistics for evaluating overall adequacy of risk prediction procedures with censored survival data.
TL;DR: A simple C-statistic is presented which consistently estimates a conventional concordance measure which is free of censoring and results from numerical studies suggest that the new procedure performs well in finite sample.
Journal ArticleDOI
Left atrial size and the risk of stroke and death : the Framingham Heart Study
TL;DR: After multivariable adjustment, LA enlargement remained a significant predictor of stroke in men and death in both sexes and appears to be partially mediated by LV mass.
Journal ArticleDOI
Body mass index, metabolic syndrome, and risk of type 2 diabetes or cardiovascular disease
James B. Meigs,Peter W.F. Wilson,Caroline S. Fox,Ramachandran S. Vasan,David M. Nathan,Lisa M. Sullivan,Ralph B. D'Agostino +6 more
TL;DR: Assessment of risk for diabetes or cardiovascular disease stratified by body mass index and the presence or absence of metabolic syndrome (MetS) or insulin resistance (IR) found people with normal weight and MetS or IR or with obesity but no MetS and IR were not uncommon in this sample.
Journal ArticleDOI
C-Reactive Protein, Fibrinogen, and Cardiovascular Disease Prediction
Stephen Kaptoge,Emanuele Di Angelantonio,Lisa Pennells,Angela M. Wood,Ian R. White,Pei Gao,Matthew G. Walker,Alexander M. W. Cargill Thompson,Nadeem Sarwar,Muriel J. Caslake,Adam S. Butterworth,Philippe Amouyel,Gerd Assmann,Stephan J. L. Bakker,Elizabeth L M Barr,Elizabeth Barrett-Connor,Emelia J. Benjamin,Cecilia Björkelund,Hermann Brenner,Eric J. Brunner,Robert Clarke,Jackie A. Cooper,Peter Cremer,Mary Cushman,Gilles R. Dagenais,Ralph B. D'Agostino,Rachel Dankner,George Davey-Smith,Dorly J. H. Deeg,Jacqueline M. Dekker,Gunnar Engström,Aaron R. Folsom,F. Gerry R. Fowkes,John Gallacher,J. Michael Gaziano,Simona Giampaoli,Richard F. Gillum,Albert Hofman,Barbara V. Howard,Erik Ingelsson,Hiroyasu Iso,Torben Jørgensen,Stefan Kiechl,Akihiko Kitamura,Yutaka Kiyohara,Wolfgang Koenig,Daan Kromhout,Lewis H. Kuller,Debbie A Lawlor,Tom W. Meade,Aulikki Nissinen,Børge G. Nordestgaard,Altan Onat,Demosthenes B. Panagiotakos,Bruce M. Psaty,Beatriz L. Rodriguez,Annika Rosengren,Veikko Salomaa,Jussi Kauhanen,Jukka T. Salonen,Jonathan A. Shaffer,Steven Shea,Ian Ford,Coen D.A. Stehouwer,Timo E. Strandberg,Robert W. Tipping,Alberto Tosetto,Sylvia Wassertheil-Smoller,Patrik Wennberg,Rudi G. J. Westendorp,Peter H. Whincup,Lars Wilhelmsen,Mark Woodward,Gordon D.O. Lowe,Nicholas J. Wareham,Kay-Tee Khaw,Naveed Sattar,Chris J. Packard,Vilmundur Gudnason,Paul M. Ridker,Mark B. Pepys,Simon G. Thompson,John Danesh +82 more
TL;DR: It is estimated that under current treatment guidelines, assessment of the CRP or fibrinogen level in people at intermediate risk for a cardiovascular event could help prevent one additional event over a period of 10 years for every 400 to 500 people screened.